| Improves function in Barth syndrome | elamipretide | Claim assessment | — | — | 2026-11-08 |
| Improves dry eye signs and symptoms | thymosin-beta-4 | Claim assessment | — | — | 2026-11-08 |
| Is safe for human administration | bpc-157 | Claim assessment | — | — | 2026-11-08 |
| Is safe for human administration | thymosin-beta-4 | Claim assessment | — | — | 2026-11-08 |
| Is safe for human administration | elamipretide | Claim assessment | — | — | 2026-11-08 |
| Is safe for human use | ghk-cu | Claim assessment | — | — | 2026-11-08 |
| Reduces knee pain | bpc-157 | Claim assessment | — | — | 2026-11-08 |
| Improves metabolic health | mots-c | Claim assessment | — | — | 2026-11-08 |
| Improves exercise capacity in primary mitochondrial myopathy | elamipretide | Claim assessment | — | — | 2026-11-08 |
| Improves signs of skin aging | ghk-cu | Claim assessment | — | — | 2026-11-08 |
| Insulin sensitivity, glucose control or body weight | mots-c | Certainty (GRADE) | Insufficient information to assess | 0 | 2026-11-08 |
| Muscle strength, exercise capacity and fatigue | elamipretide | Certainty (GRADE) | Insufficient information to assess | 31 | 2026-11-08 |
| Six-minute walk distance and fatigue | elamipretide | Certainty (GRADE) | Low certainty | 284 | 2026-11-08 |
| Adverse events, including injection-site reactions, and discontinuations | elamipretide | Certainty (GRADE) | Insufficient information to assess | 655 | 2026-11-08 |
| Adverse events, serious adverse events and discontinuations | bpc-157 | Certainty (GRADE) | Insufficient information to assess | 14 | 2026-11-08 |
| Ocular discomfort and corneal staining | thymosin-beta-4 | Certainty (GRADE) | Very low certainty | 81 | 2026-11-08 |
| Adverse events, serious adverse events and discontinuations | thymosin-beta-4 | Certainty (GRADE) | Insufficient information to assess | 318 | 2026-11-08 |
| Knee pain intensity | bpc-157 | Certainty (GRADE) | Very low certainty | 17 | 2026-11-08 |
| Wrinkles and skin quality, measured or rated | ghk-cu | Certainty (GRADE) | Very low certainty | 14 | 2026-11-08 |
| Adverse events, including skin reactions | ghk-cu | Certainty (GRADE) | Very low certainty | 1001 | 2026-11-08 |
| Improves gastrointestinal conditions | bpc-157 | Claim assessment | — | — | 2026-11-08 |
| Is safe for human administration | mots-c | Claim assessment | — | — | 2026-11-08 |
| Is safe for human administration | tb-500 | Claim assessment | — | — | 2026-11-08 |
| Supports soft-tissue injury recovery | tb-500 | Claim assessment | — | — | 2026-11-08 |
| Improves muscle injury recovery | bpc-157 | Claim assessment | — | — | 2026-11-08 |
| Supports tendon injury recovery | bpc-157 | Claim assessment | — | — | 2026-11-08 |
| Adverse events, serious adverse events and discontinuations | tb-500 | Certainty (GRADE) | Insufficient information to assess | — | 2026-11-08 |
| Function and return to activity | tb-500 | Certainty (GRADE) | Insufficient information to assess | — | 2026-11-08 |
| Clinical response or remission | bpc-157 | Certainty (GRADE) | Insufficient information to assess | — | 2026-11-08 |
| Time to return to activity | bpc-157 | Certainty (GRADE) | Insufficient information to assess | — | 2026-11-08 |
| Function and return to activity | bpc-157 | Certainty (GRADE) | Insufficient information to assess | — | 2026-11-08 |
| Adverse events, serious adverse events and discontinuations | mots-c | Certainty (GRADE) | Insufficient information to assess | — | 2026-11-08 |
| An Intermediate Size Expanded Access Protocol of Elamipretide | elamipretide | Study recordOther design | — | — | 2026-11-08 |
| Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD) | elamipretide | Study recordOther design | — | 102 | 2026-11-08 |
| FRDA Investigator Initiated Study (IIS) With Elamipretide | elamipretide | Study recordOther design | — | 20 | 2026-11-08 |
| Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 | thymosin-beta-4 | Study recordOther design | — | 70 | 2026-11-08 |
| ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD) | elamipretide | Study recordOther design | — | 313 | 2026-11-08 |
| Study of Healthy Aging and Physical Function With Elamipretide | elamipretide | Study recordOther design | — | — | 2026-11-08 |
| BPC 157 for Acute Hamstring Muscle Strain Repair | bpc-157 | Study recordOther design | — | — | 2026-11-08 |
| Topical GHK-Cu Gel for Acute Skin Wound Healing | ghk-cu | Study recordOther design | — | — | 2026-11-08 |
| TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD | tb-500 | Study recordOther design | — | — | 2026-11-08 |
| MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity | mots-c | Study recordOther design | — | — | 2026-11-08 |
| Clinical Trial in Patients With Barth Syndrome- 4TAZPower | elamipretide | Study recordOther design | — | — | 2026-11-08 |
| Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction | thymosin-beta-4 | Study recordOther design | — | — | 2026-11-08 |
| Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery | bpc-157 | Study recordOther design | — | — | 2026-11-08 |
| A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderly | elamipretide | Study recordOther design | — | 41 | 2026-11-08 |
| A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration | elamipretide | Study recordOther design | — | 20 | 2026-11-08 |
| Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy | elamipretide | Study recordOther design | — | 36 | 2026-11-08 |
| A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Bendavia™ (MTP-131) in Patients With Heart Failure | elamipretide | Study recordOther design | — | 0 | 2026-11-08 |
| A Phase 1 Study Investigating the Safety and Pharmacokinetics of Repeat-dose Intravenous Infusion of MTP-131 in Subjects With Impaired Renal Function | elamipretide | Study recordOther design | — | 23 | 2026-11-08 |
| Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1 | thymosin-beta-4 | Study recordOther design | — | 317 | 2026-11-08 |
| Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1 | thymosin-beta-4 | Study recordOther design | — | 18 | 2026-11-08 |
| PCO-02 - Safety and Pharmacokinetics Trial | bpc-157 | Study recordOther design | — | — | 2026-11-08 |
| A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED) | elamipretide | Study recordOther design | — | 22 | 2026-11-08 |
| A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic Neuropathy | elamipretide | Study recordOther design | — | 12 | 2026-11-08 |
| Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction | elamipretide | Study recordOther design | — | 71 | 2026-11-08 |
| Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study | elamipretide | Study recordOther design | — | 30 | 2026-11-08 |
| A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction | elamipretide | Study recordOther design | — | 46 | 2026-11-08 |
| An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration | elamipretide | Study recordSingle-arm trial | — | 40 | 2026-11-08 |
| A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure | elamipretide | Study recordOther design | — | 308 | 2026-11-08 |
| Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2 | thymosin-beta-4 | Study recordOther design | — | 601 | 2026-11-08 |
| Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM) | elamipretide | Study recordSingle-arm trial | — | 28 | 2026-11-08 |
| Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3 | thymosin-beta-4 | Study recordOther design | — | 700 | 2026-11-08 |
| A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers | thymosin-beta-4 | Study recordOther design | — | 54 | 2026-11-08 |
| A Phase 1b Study of Thymosin Beta 4 in Healthy Volunteers | thymosin-beta-4 | Study recordOther design | — | 30 | 2026-11-08 |
| Ocular discomfort (OSDI questionnaire) | thymosin-beta-4 | Risk of biasRandomized controlled trial | High certainty | 9 | 2026-11-08 |
| Total corneal fluorescein staining | thymosin-beta-4 | Risk of biasRandomized controlled trial | High certainty | 9 | 2026-11-08 |
| Tear film breakup time | thymosin-beta-4 | Risk of biasRandomized controlled trial | High certainty | 9 | 2026-11-08 |
| Tear volume production | thymosin-beta-4 | Risk of biasRandomized controlled trial | High certainty | 9 | 2026-11-08 |
| Safety and tolerability | thymosin-beta-4 | Risk of biasRandomized controlled trial | High certainty | 9 | 2026-11-08 |
| From proteomic multimarker profiling to interesting proteins: thymosin-β(4) and kininogen-1 as new potential biomarkers for inflammatory hepatic lesions. | thymosin-beta-4 | Study recordCase-control study | — | — | 2026-11-08 |
| Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. | thymosin-beta-4 | Study recordRandomized controlled trial | — | 9 | 2026-11-08 |
| [The clinical significance of thymosin β4 expression in human non-small cell lung cancer]. | thymosin-beta-4 | Study recordOther design | — | — | 2026-11-08 |
| Biochemical characterization of thymic hormones in thymoma tissues. | thymosin-beta-4 | Study recordOther design | — | 3 | 2026-11-08 |
| Multiplexed molecular descriptors of pressure ulcers defined by imaging mass spectrometry. | thymosin-beta-4 | Study recordUncontrolled pilot study | — | — | 2026-11-08 |
| Intraocular expression of thymosin β4 in proliferative diabetic retinopathy. | thymosin-beta-4 | Study recordCross-sectional study | — | — | 2026-11-08 |
| Elevated expression of thymosin β4, vascular endothelial growth factor (VEGF), and hypoxia inducible factor (HIF)-1α in early-stage cervical cancers. | thymosin-beta-4 | Study recordCross-sectional study | — | — | 2026-11-08 |
| Associations of Serum MOTS-c with Exercise Capacity and Antioxidant Markers in Young Males: A Cross-Sectional Study. | mots-c | Study recordCross-sectional study | — | 30 | 2026-11-08 |
| A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa | thymosin-beta-4 | Study recordOther design | — | 30 | 2026-11-08 |
| Study of Thymosin Beta 4 in Patients With Pressure Ulcers | thymosin-beta-4 | Study recordOther design | — | 72 | 2026-11-08 |
| A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds | thymosin-beta-4 | Study recordOther design | — | 12 | 2026-11-08 |
| A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers | thymosin-beta-4 | Study recordOther design | — | 0 | 2026-11-08 |
| Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers | thymosin-beta-4 | Study recordOther design | — | 72 | 2026-11-08 |
| Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults | elamipretide | Study recordOther design | — | 40 | 2026-11-08 |
| A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction | thymosin-beta-4 | Study recordOther design | — | 0 | 2026-11-08 |
| Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye | thymosin-beta-4 | Study recordOther design | — | 72 | 2026-11-08 |
| Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without Bendavia | elamipretide | Study recordOther design | — | 12 | 2026-11-08 |
| The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking | elamipretide | Study recordOther design | — | 6 | 2026-11-08 |
| A Phase 1 Study Examining the Pharmacokinetics and Tolerability of a Single Oral Dose of Bendavia (MTP-131) | elamipretide | Study recordOther design | — | 30 | 2026-11-08 |
| Safety and Pharmacokinetic (PK) Study of Oral Bendavia Administered for 7 Days | elamipretide | Study recordOther design | — | 30 | 2026-11-08 |
| Increased levels of thymosin β4 in synovial fluid of patients with rheumatoid arthritis: association of thymosin β4 with other factors that are involved in inflammation and bone erosion in joints. | thymosin-beta-4 | Study recordCross-sectional study | — | — | 2026-11-08 |
| Association between serum thymosin β4 levels of rheumatoid arthritis patients and disease activity and response to therapy. | thymosin-beta-4 | Study recordProspective cohort | — | 40 | 2026-11-08 |
| Identification of tubulin beta chain, thymosin beta-4-like protein 3, and cytochrome b-c₁ complex subunit 1 as serological diagnostic biomarkers of gastric cancer. | thymosin-beta-4 | Study recordCase-control study | — | — | 2026-11-08 |
| Quantification of thymosin beta(4) in human cerebrospinal fluid using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. | thymosin-beta-4 | Study recordOther design | — | — | 2026-11-08 |
| Expression patterns of Thymosin β4 and cancer stem cell marker CD133 in ovarian cancers. | thymosin-beta-4 | Study recordOther design | — | — | 2026-11-08 |
| Thymosin beta(4) and beta(10) levels in pre-term newborn oral cavity and foetal salivary glands evidence a switch of secretion during foetal development. | thymosin-beta-4 | Study recordCross-sectional study | — | — | 2026-11-08 |
| Evaluation of thymosin β4 in the regulation of epithelial-mesenchymal transformation in urothelial carcinoma. | thymosin-beta-4 | Study recordOther design | — | — | 2026-11-08 |
| MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. | thymosin-beta-4 | Study recordOther design | — | 70 | 2026-11-08 |
| Effect of vitamin A deficiency on thymosin-β4 and CD4 concentrations. | thymosin-beta-4 | Study recordCross-sectional study | — | — | 2026-11-08 |
| Serum Thymosin β4 Concentrations in Obstructive Sleep Apnea Syndrome Patients. | thymosin-beta-4 | Study recordCross-sectional study | — | — | 2026-11-08 |
| Thymosin β4 is a novel potential prognostic marker in gastrointestinal stromal tumors. | thymosin-beta-4 | Study recordCross-sectional study | — | 60 | 2026-11-08 |
| Thymosin β4 and β10 in Sjögren's syndrome: saliva proteomics and minor salivary glands expression. | thymosin-beta-4 | Study recordCross-sectional study | — | — | 2026-11-08 |
| Peptidomic Identification of Serum Peptides Diagnosing Preeclampsia. | thymosin-beta-4 | Study recordCase-control study | — | 62 | 2026-11-08 |
| Contribution of cerebrospinal fluid thymosin β4 levels to the clinical differentiation of Creutzfeldt-Jakob disease. | thymosin-beta-4 | Study recordCross-sectional study | — | — | 2026-11-08 |
| Increased thymosin β4 levels in the serum and SF of knee osteoarthritis patients correlate with disease severity. | thymosin-beta-4 | Study recordCross-sectional study | — | — | 2026-11-08 |
| Thymosin β 4 in colorectal cancer is localized predominantly at the invasion front in tumor cells undergoing epithelial mesenchymal transition. | thymosin-beta-4 | Study recordCase series | — | — | 2026-11-08 |
| Distribution of thymic hormones in thymic tumors and myasthenic thymus. | thymosin-beta-4 | Study recordCross-sectional study | — | 44 | 2026-11-08 |
| β-Thymosins and interstitial lung disease: study of a scleroderma cohort with a one-year follow-up. | thymosin-beta-4 | Study recordProspective cohort | — | — | 2026-11-08 |
| In situ proteomic analysis by MALDI imaging identifies ubiquitin and thymosin-β4 as markers of malignant intraductal pancreatic mucinous neoplasms. | thymosin-beta-4 | Study recordCross-sectional study | — | — | 2026-11-08 |
| Relationship between serum thymosin β4 levels and coronary collateral development. | thymosin-beta-4 | Study recordCross-sectional study | — | 190 | 2026-11-08 |
| 6-minute walking distance | thymosin-beta-4 | Risk of biasRandomized controlled trial | High certainty | 10 | 2026-11-08 |
| Left ventricular function | thymosin-beta-4 | Risk of biasRandomized controlled trial | High certainty | 10 | 2026-11-08 |
| Feasibility and safety | thymosin-beta-4 | Risk of biasRandomized controlled trial | High certainty | 10 | 2026-11-08 |
| Adverse events / tolerability | thymosin-beta-4 | Risk of biasRandomized controlled trial | Some concerns | — | 2026-11-08 |
| Pharmacokinetics (plasma concentration, Cmax, AUC, terminal clearance, accumulation) | thymosin-beta-4 | Risk of biasRandomized controlled trial | Some concerns | — | 2026-11-08 |
| Ocular discomfort score | thymosin-beta-4 | Risk of biasRandomized controlled trial | Some concerns | — | 2026-11-08 |
| Inferior corneal staining | thymosin-beta-4 | Risk of biasRandomized controlled trial | Some concerns | — | 2026-11-08 |
| Ocular discomfort during CAE challenge | thymosin-beta-4 | Risk of biasRandomized controlled trial | High certainty | — | 2026-11-08 |
| Central corneal staining | thymosin-beta-4 | Risk of biasRandomized controlled trial | High certainty | — | 2026-11-08 |
| Superior corneal staining | thymosin-beta-4 | Risk of biasRandomized controlled trial | High certainty | — | 2026-11-08 |
| Adverse events | thymosin-beta-4 | Risk of biasRandomized controlled trial | Some concerns | — | 2026-11-08 |
| Thymosin beta 4 is associated with collateral development in coronary artery disease. | thymosin-beta-4 | Study recordCase-control study | — | — | 2026-11-08 |
| Global Proteomics-based Identification and Validation of Thymosin Beta-4 X-Linked as a Prognostic Marker for Head and Neck Squamous Cell Carcinoma. | thymosin-beta-4 | Study recordOther design | — | — | 2026-11-08 |
| Thymosin Beta-4 Is Elevated in Women With Heart Failure With Preserved Ejection Fraction. | thymosin-beta-4 | Study recordCase-control study | — | — | 2026-11-08 |
| The expression of thymosin β4 in chronic hepatitis B combined nonalcoholic fatty liver disease. | thymosin-beta-4 | Study recordCross-sectional study | — | — | 2026-11-08 |
| Association of serum thymosin β4 with malnutrition-inflammation-atherosclerosis syndrome in peritoneal dialysis patients: a cross-sectional study. | thymosin-beta-4 | Study recordCross-sectional study | — | 76 | 2026-11-08 |
| Determination of thymosin beta4 and protein in human wound fluid after abdominal surgery. | thymosin-beta-4 | Study recordOther design | — | — | 2026-11-08 |
| Serum thymosin beta4 levels in patients with hepatitis B virus-related liver failure. | thymosin-beta-4 | Study recordCross-sectional study | — | — | 2026-11-08 |
| Safety and efficacy of autologous thymosin β4 pre-treated endothelial progenitor cell transplantation in patients with acute ST segment elevation myocardial infarction: A pilot study. | thymosin-beta-4 | Study recordRandomized controlled trial | — | 10 | 2026-11-08 |
| MALDI-imaging reveals thymosin beta-4 as an independent prognostic marker for colorectal cancer. | thymosin-beta-4 | Study recordOther design | — | — | 2026-11-08 |
| MALDI imaging mass spectrometry analysis-A new approach for protein mapping in multiple sclerosis brain lesions. | thymosin-beta-4 | Study recordOther design | — | 12 | 2026-11-08 |
| Association of thymosin β4 expression with clinicopathological parameters and clinical outcomes of bladder cancer patients. | thymosin-beta-4 | Study recordOther design | — | — | 2026-11-08 |
| Discovery of thymosin β4 as a human exerkine and growth factor. | thymosin-beta-4 | Study recordOther design | — | — | 2026-11-08 |
| Thymosinβ4: a novel assessed biomarker of the prognosis of acute-on-chronic liver failure patient? | thymosin-beta-4 | Study recordOther design | — | — | 2026-11-08 |
| A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. | thymosin-beta-4 | Study recordRandomized controlled trial | — | — | 2026-11-08 |
| Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. | thymosin-beta-4 | Study recordRandomized controlled trial | — | — | 2026-11-08 |
| Plasma levels of F-actin and F:G-actin ratio as potential new biomarkers in patients with septic shock. | thymosin-beta-4 | Study recordCross-sectional study | — | — | 2026-11-08 |
| Occurrence of thymosin beta4 in human breast cancer cells and in other cell types of the tumor microenvironment. | thymosin-beta-4 | Study recordOther design | — | — | 2026-11-08 |
| Increases in plasma Tβ4 after intracardiac cell therapy in chronic ischemic heart failure is associated with symptomatic improvement. | thymosin-beta-4 | Study recordOther design | — | — | 2026-11-08 |
| Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta 4. | thymosin-beta-4 | Study recordCase report | — | — | 2026-11-08 |
| Over-expression of thymosin β4 in granulomatous lung tissue with active pulmonary tuberculosis. | thymosin-beta-4 | Study recordCross-sectional study | — | — | 2026-11-08 |
| Adherent Scalp Flaking Score | thymosin-beta-4 | Risk of biasNonrandomized controlled study | No information | — | 2026-11-08 |
| Maximum Erythema Area | thymosin-beta-4 | Risk of biasNonrandomized controlled study | No information | — | 2026-11-08 |
| Scalp physiological conditions (transepidermal water loss, hydration, sebum secretion) | thymosin-beta-4 | Risk of biasNonrandomized controlled study | No information | — | 2026-11-08 |
| Scalp microbiome composition and diversity | thymosin-beta-4 | Risk of biasNonrandomized controlled study | No information | — | 2026-11-08 |
| Treatment-emergent adverse events | thymosin-beta-4 | Risk of biasRandomized controlled trial | Some concerns | — | 2026-11-08 |
| Dose-limiting toxicities and serious adverse events | thymosin-beta-4 | Risk of biasRandomized controlled trial | Some concerns | — | 2026-11-08 |
| Pharmacokinetic parameters | thymosin-beta-4 | Risk of biasRandomized controlled trial | Some concerns | — | 2026-11-08 |
| Safety and tolerability | thymosin-beta-4 | Risk of biasRandomized controlled trial | High certainty | 73 | 2026-11-08 |
| Complete wound healing | thymosin-beta-4 | Risk of biasRandomized controlled trial | High certainty | 73 | 2026-11-08 |
| Rate of wound healing | thymosin-beta-4 | Risk of biasRandomized controlled trial | High certainty | 73 | 2026-11-08 |
| Thymosin β4, a potential marker of malignancy and prognosis in hepatocellular carcinoma. | thymosin-beta-4 | Study recordCase-control study | — | 540 | 2026-11-08 |
| Aberrant Expression of Thymosin Beta-4 Correlates With Advanced Disease and BRAF V600E Mutation in Thyroid Cancer. | thymosin-beta-4 | Study recordCross-sectional study | — | — | 2026-11-08 |
| Role of Thymosin Beta 4 in the diagnosis of Nonalcoholic Fatty Liver and its relation to Metabolic Syndrome in Egyptian patients. | thymosin-beta-4 | Study recordCase-control study | — | 80 | 2026-11-08 |
| Recombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis. | thymosin-beta-4 | Study recordNonrandomized controlled study | — | — | 2026-11-08 |
| Association between thymosin beta4 and non-alcoholic fatty liver disease. | thymosin-beta-4 | Study recordCase-control study | — | — | 2026-11-08 |
| Thymosin beta-4 overexpression correlates with high-risk groups in gastric gastrointestinal stromal tumors: A retrospective analysis by immunohistochemistry. | thymosin-beta-4 | Study recordOther design | — | — | 2026-11-08 |
| Exploring the Relationship Between Thymosin β4 Protein and First Myocardial Infarction on the Basis of Proteomics. | thymosin-beta-4 | Study recordCase-control study | — | — | 2026-11-08 |
| Serum thymosin beta4 as a noninvasive biomarker in patients with nonalcoholic steatohepatitis. | thymosin-beta-4 | Study recordCross-sectional study | — | — | 2026-11-08 |
| Thymosin β4 and β10 are highly expressed at the deep infiltrative margins of colorectal cancer - A mass spectrometry analysis. | thymosin-beta-4 | Study recordCross-sectional study | — | 18 | 2026-11-08 |
| A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. | thymosin-beta-4 | Study recordRandomized controlled trial | — | — | 2026-11-08 |
| Comparative proteomic analysis of plasma of children with congenital heart disease. | thymosin-beta-4 | Study recordCase-control study | — | — | 2026-11-08 |
| Identification and quantification of thymosin beta4 in human saliva and tears. | thymosin-beta-4 | Study recordCross-sectional study | — | — | 2026-11-08 |
| F-Actin is associated with a worsening qSOFA score and intensive care unit admission in emergency department patients at risk for sepsis. | thymosin-beta-4 | Study recordProspective cohort | — | 203 | 2026-11-08 |
| Endogenous Thymosin β4 Expression in Sacrococcygeal Pilonidal Sinus Disease: A Retrospective, Immunohistochemical Analysis of Excisional Skin Biopsy Samples. | thymosin-beta-4 | Study recordCase series | — | 31 | 2026-11-08 |
| Conjunctival expression of thymosin-beta4 in vernal keratoconjunctivitis. | thymosin-beta-4 | Study recordCross-sectional study | — | — | 2026-11-08 |
| Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing. | thymosin-beta-4 | Study recordRandomized controlled trial | — | 21 | 2026-11-08 |
| The effect of thymosin treatment of venous ulcers. | thymosin-beta-4 | Study recordRandomized controlled trial | — | 73 | 2026-11-08 |
| Thymosin beta 4 and thymosin beta 10 expression in hepatocellular carcinoma. | thymosin-beta-4 | Study recordCase series | — | 23 | 2026-11-08 |
| Thymosin ß4 expression in colorectal polyps and adenomas. | thymosin-beta-4 | Study recordCross-sectional study | — | — | 2026-11-08 |
| Thymosin beta4 levels after successful primary percutaneous coronary intervention for acute myocardial infarction. | thymosin-beta-4 | Study recordCase-control study | — | 48 | 2026-11-08 |
| 6-minute walk test distance | elamipretide | Risk of biasSingle-arm trial | Serious concern | — | 2026-11-08 |
| BTHS-SA Total Fatigue score | elamipretide | Risk of biasSingle-arm trial | Serious concern | — | 2026-11-08 |
| Safety and tolerability | elamipretide | Risk of biasSingle-arm trial | Serious concern | — | 2026-11-08 |
| 3D echocardiographic left ventricular volumes | elamipretide | Risk of biasSingle-arm trial | Serious concern | — | 2026-11-08 |
| MLCL/CL ratio | elamipretide | Risk of biasSingle-arm trial | Serious concern | — | 2026-11-08 |
| Mitochondrial energetic capacity (ATPmax) during exercise | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 39 | 2026-11-08 |
| Resting mitochondrial coupling (P/O, ATP supply per O2 uptake) | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 39 | 2026-11-08 |
| Volitional fatigue resistance | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 39 | 2026-11-08 |
| Stenotic kidney fractional hypoxia | elamipretide | Risk of biasRandomized controlled trial | High certainty | 16 | 2026-11-08 |
| Stenotic kidney renal blood flow | elamipretide | Risk of biasRandomized controlled trial | High certainty | 16 | 2026-11-08 |
| Estimated glomerular filtration rate | elamipretide | Risk of biasRandomized controlled trial | High certainty | 16 | 2026-11-08 |
| Systolic blood pressure | elamipretide | Risk of biasRandomized controlled trial | High certainty | 16 | 2026-11-08 |
| Serum HtrA2 level | elamipretide | Risk of biasRandomized controlled trial | High certainty | 35 | 2026-11-08 |
| CK-MB area under the curve (biomarker infarct size) | elamipretide | Risk of biasRandomized controlled trial | High certainty | 300 | 2026-11-08 |
| Troponin I area under the curve (biomarker infarct size) | elamipretide | Risk of biasRandomized controlled trial | High certainty | 300 | 2026-11-08 |
| Myocardial salvage index | elamipretide | Risk of biasRandomized controlled trial | High certainty | 300 | 2026-11-08 |
| Infarcted area | thymosin-beta-4 | Risk of biasRandomized controlled trial | High certainty | 96 | 2026-11-08 |
| Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. | elamipretide | Study recordSingle-arm trial | — | — | 2026-11-08 |
| In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial. | elamipretide | Study recordRandomized controlled trial | — | 39 | 2026-11-08 |
| Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis. | elamipretide | Study recordRandomized controlled trial | — | 16 | 2026-11-08 |
| The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction. | elamipretide | Study recordRandomized controlled trial | — | 35 | 2026-11-08 |
| Urinary mitochondrial DNA copy number identifies renal mitochondrial injury in renovascular hypertensive patients undergoing renal revascularization: A Pilot Study. | elamipretide | Study recordOther design | — | 19 | 2026-11-08 |
| Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial). | elamipretide | Study recordRandomized controlled trial | — | 300 | 2026-11-08 |
| Low periconceptional maternal serum thymosin alpha 1 levels are associated with blighted pregnancies. | thymosin-beta-4 | Study recordProspective cohort | — | 28 | 2026-11-08 |
| Serum levels of immunoreactive thymosin alpha 1 and thymosin beta 4 in large cohorts of healthy adults. | thymosin-beta-4 | Study recordCross-sectional study | — | 681 | 2026-11-08 |
| Thymosin alpha 1 and thymosin beta 4 in serum: comparison of normal, cord, homosexual and AIDS serum. | thymosin-beta-4 | Study recordCross-sectional study | — | — | 2026-11-08 |
| Modulation of thymosin alpha 1 and thymosin beta 4 levels and peripheral blood mononuclear cell subsets during experimental rhinovirus colds. | thymosin-beta-4 | Study recordOther design | — | — | 2026-11-08 |
| Defective in vitro gamma interferon production and elevated serum immunoreactive thymosin beta 4 levels in patients with inflammatory bowel disease. | thymosin-beta-4 | Study recordCross-sectional study | — | — | 2026-11-08 |
| Modulation of thymosin beta 4 by estrogen. | thymosin-beta-4 | Study recordCross-sectional study | — | 87 | 2026-11-08 |
| Thymosins: structure, function and therapeutic applications. | thymosin-beta-4 | Study recordOther design | — | — | 2026-11-08 |
| Malignant thymoma associated with T-cell lymphocytosis. A case report with immunophenotypic and gene rearrangement analysis. | thymosin-beta-4 | Study recordCase report | — | 1 | 2026-11-08 |
| Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. | thymosin-beta-4 | Study recordRandomized controlled trial | — | 96 | 2026-11-08 |
| Association between Thymosin beta-4, acute kidney injury, and mortality in patients with sepsis: An observational cohort study. | thymosin-beta-4 | Study recordProspective cohort | — | 191 | 2026-11-08 |
| Longitudinal Trends of Salivary Oxidized Thymosin β4 and β10 in Preterm Infants with Bronchopulmonary Dysplasia. | thymosin-beta-4 | Study recordOther design | — | 18 | 2026-11-08 |
| Hypomethylation of thymosin β4 promoter is associated with glucocorticoid therapy in patients with acute-on-chronic hepatitis B-induced liver failure. | thymosin-beta-4 | Study recordCase-control study | — | — | 2026-11-08 |
| Association Between Thymosin β4 and Coronary Arterial Lesions in Children with Kawasaki Disease. | thymosin-beta-4 | Study recordCase-control study | — | — | 2026-11-08 |
| Hypermethylation of thymosin β4 predicts a poor prognosis for patients with acute-on-chronic hepatitis B liver failure. | thymosin-beta-4 | Study recordOther design | — | — | 2026-11-08 |
| Geographic atrophy area | elamipretide | Risk of biasSingle-arm trial | Serious concern | 19 | 2026-11-07 |
| Low-luminance questionnaire (LLQ) self-reported function | elamipretide | Risk of biasSingle-arm trial | Serious concern | 19 | 2026-11-07 |
| Change in left ventricular end systolic volume (LVESV) | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 71 | 2026-11-07 |
| Change in left ventricular ejection fraction (LVEF) | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 71 | 2026-11-07 |
| Study drug-related adverse events | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 71 | 2026-11-07 |
| 6-minute walk test distance | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 30 | 2026-11-07 |
| PMMSA Total Fatigue score | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 30 | 2026-11-07 |
| PMMSA Total Fatigue During Activities score | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 30 | 2026-11-07 |
| Neuro-QoL Fatigue Short Form | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 30 | 2026-11-07 |
| Patient Global Assessment | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 30 | 2026-11-07 |
| Physician Global Assessment | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 30 | 2026-11-07 |
| Triple Timed Up and Go test | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 30 | 2026-11-07 |
| Wrist and hip accelerometry | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 30 | 2026-11-07 |
| Adverse events | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 30 | 2026-11-07 |
| Infarct size by CK-MB area under the curve over 72 h | elamipretide | Risk of biasRandomized controlled trial | Some concerns | — | 2026-11-07 |
| Pre-specified MRI, angiographic and electrocardiographic outcomes | elamipretide | Risk of biasRandomized controlled trial | High certainty | — | 2026-11-07 |
| Clinical outcomes | elamipretide | Risk of biasRandomized controlled trial | High certainty | — | 2026-11-07 |
| Safety and tolerability | elamipretide | Risk of biasRandomized controlled trial | High certainty | — | 2026-11-07 |
| Left ventricular end-diastolic volume | elamipretide | Risk of biasRandomized controlled trial | High certainty | 36 | 2026-11-07 |
| Left ventricular end-systolic volume | elamipretide | Risk of biasRandomized controlled trial | High certainty | 36 | 2026-11-07 |
| Serious adverse events | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 36 | 2026-11-07 |
| Tolerability of elamipretide | elamipretide | Risk of biasCase report | Serious concern | 1 | 2026-11-07 |
| Cardiac transplantation and clinical course | elamipretide | Risk of biasCase report | Serious concern | 1 | 2026-11-07 |
| Explanted heart pathology | elamipretide | Risk of biasCase report | Serious concern | 1 | 2026-11-07 |
| Clinical heart failure status and heart transplant listing status | elamipretide | Risk of biasCase report | Serious concern | 1 | 2026-11-07 |
| Symptoms (dysarthria, dysphagia, gait) | elamipretide | Risk of biasCase report | Serious concern | 1 | 2026-11-07 |
| 6-minute walk test | elamipretide | Risk of biasCase report | Serious concern | 1 | 2026-11-07 |
| 5 times sit-to-stand test | elamipretide | Risk of biasCase report | Serious concern | 1 | 2026-11-07 |
| Mean change from baseline in low-luminance best-corrected visual acuity (LL BCVA) | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 176 | 2026-11-07 |
| Change from baseline in square-root converted geographic atrophy area | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 176 | 2026-11-07 |
| Progression of macular percentage of total ellipsoid zone attenuation/loss | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 176 | 2026-11-07 |
| Progression of macular percentage of partial ellipsoid zone attenuation/degradation | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 176 | 2026-11-07 |
| Proportion of patients with a gain of 10 or more letters in LL BCVA | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 176 | 2026-11-07 |
| Incidence and severity of adverse events | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 176 | 2026-11-07 |
| Adverse events | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 12 | 2026-11-07 |
| Change from baseline in best-corrected visual acuity (BCVA) | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 12 | 2026-11-07 |
| Central visual field mean deviation (Humphrey automated visual field central region) | elamipretide | Risk of biasRandomized controlled trial | High certainty | 12 | 2026-11-07 |
| 6-minute walk test distance | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 218 | 2026-11-07 |
| PMMSA total fatigue score | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 218 | 2026-11-07 |
| Adverse events | elamipretide | Risk of biasRandomized controlled trial | High certainty | 218 | 2026-11-07 |
| Accuracy of clustering patients by functional status from wearable physiological data | elamipretide | Risk of biasRandomized controlled trial | High certainty | 12 | 2026-11-07 |
| Accuracy of clustering responders vs non-responders to elamipretide | elamipretide | Risk of biasRandomized controlled trial | High certainty | 12 | 2026-11-07 |
| 6-minute walk test distance | elamipretide | Risk of biasRetrospective cohort | No information | — | 2026-11-07 |
| Muscle strength by handheld dynamometry | elamipretide | Risk of biasRetrospective cohort | No information | — | 2026-11-07 |
| 5 times sit-to-stand | elamipretide | Risk of biasRetrospective cohort | No information | — | 2026-11-07 |
| Multi-domain responder index | elamipretide | Risk of biasRetrospective cohort | No information | — | 2026-11-07 |
| Left ventricular stroke volume | elamipretide | Risk of biasRetrospective cohort | No information | — | 2026-11-07 |
| Change in 6-minute walk test distance | elamipretide | Risk of biasRandomized controlled trial | High certainty | 36 | 2026-11-07 |
| Cardiopulmonary exercise testing parameters | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 36 | 2026-11-07 |
| Participant-reported symptoms | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 36 | 2026-11-07 |
| Serum and urinary biomarkers | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 36 | 2026-11-07 |
| Safety and tolerability | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 36 | 2026-11-07 |
| Adverse events and tolerability | elamipretide | Risk of biasSingle-arm trial | Serious concern | 21 | 2026-11-07 |
| Normal-luminance best-corrected visual acuity (BCVA) | elamipretide | Risk of biasSingle-arm trial | Serious concern | 21 | 2026-11-07 |
| Low-luminance best-corrected visual acuity (LLVA) | elamipretide | Risk of biasSingle-arm trial | Serious concern | 21 | 2026-11-07 |
| Normal-luminance binocular reading acuity (NLRA) | elamipretide | Risk of biasSingle-arm trial | Serious concern | 21 | 2026-11-07 |
| Low-luminance binocular reading acuity (LLRA) | elamipretide | Risk of biasSingle-arm trial | Serious concern | 21 | 2026-11-07 |
| RPE-drusen complex volume by OCT | elamipretide | Risk of biasSingle-arm trial | Serious concern | 21 | 2026-11-07 |
| Fundus autofluorescence | elamipretide | Risk of biasSingle-arm trial | Serious concern | 21 | 2026-11-07 |
| Mesopic microperimetry | elamipretide | Risk of biasSingle-arm trial | Serious concern | 21 | 2026-11-07 |
| Dark adaptation | elamipretide | Risk of biasSingle-arm trial | Serious concern | 21 | 2026-11-07 |
| Safety and tolerability (adverse events) | elamipretide | Risk of biasSingle-arm trial | Serious concern | 19 | 2026-11-07 |
| Normal-luminance best-corrected visual acuity (BCVA) | elamipretide | Risk of biasSingle-arm trial | Serious concern | 19 | 2026-11-07 |
| Low-luminance best-corrected visual acuity (LLBCVA) | elamipretide | Risk of biasSingle-arm trial | Serious concern | 19 | 2026-11-07 |
| Low-luminance binocular reading acuity (LLBRA) | elamipretide | Risk of biasSingle-arm trial | Serious concern | 19 | 2026-11-07 |
| Normal-luminance binocular reading acuity (NLBRA) | elamipretide | Risk of biasSingle-arm trial | Serious concern | 19 | 2026-11-07 |
| Cardiac pathology in a patient with a novel pathogenic variant c.703del (p.Ile235SerfsTer4) of the TAFAZZIN gene. | elamipretide | Study recordCase report | — | 1 | 2026-11-07 |
| Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report. | elamipretide | Study recordCase report | — | 1 | 2026-11-07 |
| Expanded-access use of elamipretide in a patient with membrane protein-associated neurodegeneration. | elamipretide | Study recordCase report | — | 1 | 2026-11-07 |
| ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation. | elamipretide | Study recordRandomized controlled trial | — | 176 | 2026-11-07 |
| Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial. | elamipretide | Study recordRandomized controlled trial | — | 12 | 2026-11-07 |
| Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. | elamipretide | Study recordRandomized controlled trial | — | 218 | 2026-11-07 |
| Use of Elamipretide in patients assigned treatment in the compassionate use program: Case series in pediatric patients with rare orphan diseases. | elamipretide | Study recordCase series | — | — | 2026-11-07 |
| Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data. | elamipretide | Study recordRandomized controlled trial | — | 12 | 2026-11-07 |
| Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome. | elamipretide | Study recordRetrospective cohort | — | — | 2026-11-07 |
| Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. | elamipretide | Study recordRandomized controlled trial | — | 36 | 2026-11-07 |
| A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. | elamipretide | Study recordRandomized controlled trial | — | 12 | 2026-11-07 |
| Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study. | elamipretide | Study recordSingle-arm trial | — | 21 | 2026-11-07 |
| Phase 1 Clinical Trial of Elamipretide in Dry Age-Related Macular Degeneration and Noncentral Geographic Atrophy: ReCLAIM NCGA Study. | elamipretide | Study recordSingle-arm trial | — | 19 | 2026-11-07 |
| Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. | elamipretide | Study recordRandomized controlled trial | — | 71 | 2026-11-07 |
| A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. | elamipretide | Study recordRandomized controlled trial | — | 30 | 2026-11-07 |
| EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. | elamipretide | Study recordRandomized controlled trial | — | — | 2026-11-07 |
| Initial Psychometric Evaluation of the Barth Syndrome Symptom Assessment (BTHS-SA) for Adolescents and Adults in a Phase 2 Clinical Study. | elamipretide | Study recordRandomized controlled trial | — | 12 | 2026-11-07 |
| The mitochondrial antioxidant SS-31 increases SIRT1 levels and ameliorates inflammation, oxidative stress and leukocyte-endothelium interactions in type 2 diabetes. | elamipretide | Study recordOther design | — | — | 2026-11-07 |
| Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. | elamipretide | Study recordRandomized controlled trial | — | 36 | 2026-11-07 |
| Left ventricular ejection fraction (LVEF) | elamipretide | Risk of biasCase report | Serious concern | 1 | 2026-11-07 |
| Mitral regurgitation severity | elamipretide | Risk of biasCase report | Serious concern | 1 | 2026-11-07 |
| Ross heart failure class | elamipretide | Risk of biasCase report | Serious concern | 1 | 2026-11-07 |
| Functional capacity / exercise tolerance | elamipretide | Risk of biasCase report | Serious concern | 1 | 2026-11-07 |
| Nutritional status | elamipretide | Risk of biasCase report | Serious concern | 1 | 2026-11-07 |
| Health-related quality of life | elamipretide | Risk of biasCase report | Serious concern | 1 | 2026-11-07 |
| Return to school | elamipretide | Risk of biasCase report | Serious concern | 1 | 2026-11-07 |
| Heart transplant listing status | elamipretide | Risk of biasCase report | Serious concern | 1 | 2026-11-07 |
| Adverse events / tolerability | elamipretide | Risk of biasCase report | Serious concern | 1 | 2026-11-07 |
| Symptoms and quality of life | elamipretide | Risk of biasCase series | Serious concern | 2 | 2026-11-07 |
| Tolerability | elamipretide | Risk of biasCase series | Serious concern | 2 | 2026-11-07 |
| Left ventricular ejection fraction | elamipretide | Risk of biasCase report | Serious concern | 1 | 2026-11-07 |
| Oxygen weaning and hospital discharge | elamipretide | Risk of biasCase report | Serious concern | 1 | 2026-11-07 |
| Six-minute walk test distance, overall trial population | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 218 | 2026-11-07 |
| Six-minute walk test distance, prespecified nDNA and mtDNA subgroups | elamipretide | Risk of biasRandomized controlled trial | Some concerns | 218 | 2026-11-07 |
| Six-minute walk test change, mtDNA replisome post hoc cohort | elamipretide | Risk of biasRandomized controlled trial | High certainty | 218 | 2026-11-07 |
| Six-minute walk test change, replisome subjects with CPEO | elamipretide | Risk of biasRandomized controlled trial | High certainty | 218 | 2026-11-07 |
| Exposure-response: plasma elamipretide concentration vs 6MWT improvement, nDNA cohort | elamipretide | Risk of biasRandomized controlled trial | High certainty | 218 | 2026-11-07 |
| Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction. | mots-c | Study recordCross-sectional study | — | 40 | 2026-11-07 |
| Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals. | mots-c | Study recordCross-sectional study | — | — | 2026-11-07 |
| Adropin and MOTS-c as new peptides: Do levels change in neurodegenerative diseases and ischemic stroke? | mots-c | Study recordCase-control study | — | — | 2026-11-07 |
| Lipids and insulin regulate mitochondrial-derived peptide (MOTS-c) in PCOS and healthy subjects. | mots-c | Study recordOther design | — | — | 2026-11-07 |
| The Effect of Chronic Endurance Exercise on Serum Levels of MOTS-c and Humanin in Professional Athletes. | mots-c | Study recordCross-sectional study | — | 105 | 2026-11-07 |
| Alterations in circulating mitochondrial signals at hospital admission for COPD exacerbation. | mots-c | Study recordProspective cohort | — | — | 2026-11-07 |
| Reduced skeletal muscle expression of mitochondrial-derived peptides humanin and MOTS-C and Nrf2 in chronic kidney disease. | mots-c | Study recordCross-sectional study | — | — | 2026-11-07 |
| Changes in MOTS-c Level in the Blood of Pregnant Women with Metabolic Disorders. | mots-c | Study recordCross-sectional study | — | — | 2026-11-07 |
| A possible role for mitochondrial-derived peptides humanin and MOTS-c in patients with Q fever fatigue syndrome and chronic fatigue syndrome. | mots-c | Study recordCross-sectional study | — | 40 | 2026-11-07 |
| Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. | mots-c | Study recordRandomized controlled trial | — | — | 2026-11-07 |
| Racial differences in circulating mitochondria-derived peptides may contribute to prostate cancer health disparities. | mots-c | Study recordCase-control study | — | 198 | 2026-11-07 |
| Prediction of Post-Acute-Sequelae of COVID-19 by Cargo Protein Biomarkers of Blood Total Extracellular Vesicles in Acute COVID-19. | mots-c | Study recordOther design | — | — | 2026-11-07 |
| Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance. | mots-c | Study recordCase-control study | — | — | 2026-11-07 |
| The Relationship Between MOTS-c K14Q Polymorphism and Sarcopenia, Blood Lipids, and Mental Health in Older Korean Adults. | mots-c | Study recordCross-sectional study | — | 683 | 2026-11-07 |
| Mitochondrial-Derived Peptides Are Down Regulated in Diabetes Subjects. | mots-c | Study recordCross-sectional study | — | 225 | 2026-11-07 |
| SARS-CoV-2 and Mitochondrial Proteins in Neural-Derived Exosomes of COVID-19. | mots-c | Study recordCross-sectional study | — | — | 2026-11-07 |
| Elamipretide in pediatric Barth syndrome: from heart failure to school return. | elamipretide | Study recordCase report | — | 1 | 2026-11-07 |
| Expanded-Access Use of Elamipretide Improves Quality of Life in Patients With Rare Mitochondrial Disorders Characterized by Ophthalmic Symptoms: A Case Series. | elamipretide | Study recordCase series | — | 2 | 2026-11-07 |
| Expanded-access use of elamipretide in a newborn with Barth syndrome: a case report. | elamipretide | Study recordCase report | — | 1 | 2026-11-07 |
| Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial. | elamipretide | Study recordRandomized controlled trial | — | 218 | 2026-11-07 |
| Relationship between the mitochondria-derived peptide MOTS-c and insulin resistance in obstructive sleep apnea. | mots-c | Study recordCross-sectional study | — | 90 | 2026-11-07 |
| Circulating PGC-1α and MOTS-c Peptide as Potential Mitochondrial Biomarkers in Patients Undergoing Aortic Valve Replacement. | mots-c | Study recordCross-sectional study | — | — | 2026-11-07 |
| Plasma mitochondrial derived peptides MOTS-c and SHLP2 positively associate with android and liver fat in people without diabetes. | mots-c | Study recordCross-sectional study | — | — | 2026-11-07 |
| Effects of empagliflozin and dapagliflozin on serum humanin, MOTS-c levels, nitrosative stress, and ferroptosis parameters in diabetic patients with heart failure. | mots-c | Study recordCross-sectional study | — | — | 2026-11-07 |
| The MOTS-c K14Q polymorphism in the mtDNA is associated with muscle fiber composition and muscular performance. | mots-c | Study recordCross-sectional study | — | — | 2026-11-07 |
| Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Neurohumoral and Mitochondrial Activation in Patients With Diabetes. | mots-c | Study recordProspective cohort | — | 163 | 2026-11-07 |
| Mitochondrial dysfunction is associated with cognitive impairment in adults with OSA without dementia. | mots-c | Study recordCross-sectional study | — | 268 | 2026-11-07 |
| Impact of Radiation Therapy on Serum Humanin and MOTS-c Levels in Patients with Lung or Breast Cancer. | mots-c | Study recordProspective cohort | — | — | 2026-11-07 |
| MOTS-c Serum Concentration Positively Correlates with Lower-Body Muscle Strength and Is Not Related to Maximal Oxygen Uptake-A Preliminary Study. | mots-c | Study recordCross-sectional study | — | — | 2026-11-07 |
| The relationship of circulating MOTS-c level with liver fibrosis and metabolic components in patients with metabolic dysfunction-associated fatty liver disease. | mots-c | Study recordCross-sectional study | — | 234 | 2026-11-07 |
| A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. | mots-c | Study recordCross-sectional study | — | 27527 | 2026-11-07 |
| Evaluation of Coronary Flow Level with Mots-C in Patients with STEMI Undergoing Primary PCI. | mots-c | Study recordCross-sectional study | — | — | 2026-11-07 |
| Serum MOTS-C Levels are Decreased in Obese Children and Associated with Vascular Endothelial Function. | mots-c | Study recordCross-sectional study | — | — | 2026-11-07 |
| Circulating mitochondrial-derived microproteins at rest and in response to an acute bout of endurance exercise in individuals with cerebral palsy. | mots-c | Study recordCross-sectional study | — | — | 2026-11-07 |
| Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition. | mots-c | Study recordCross-sectional study | — | — | 2026-11-07 |
| Circulating levels of mitochondrial oxidative stress-related peptides MOTS-c and Romo1 in stable COPD: A cross-sectional study. | mots-c | Study recordCross-sectional study | — | — | 2026-11-07 |
| Evaluation of Serum Humanin and MOTS-c Peptide Levels in Patients with COVID-19 and Healthy Subjects. | mots-c | Study recordCase-control study | — | — | 2026-11-07 |
| Comparison of Serum Mitochondrial Open Reading Frame of the 12S rRNA-c (MOTS-c) Levels in Patients With Multiple Sclerosis and Healthy Controls. | mots-c | Study recordCase-control study | — | — | 2026-11-07 |
| Serum MOTS-c levels remain unchanged in patients with preeclampsia. | mots-c | Study recordCase-control study | — | 90 | 2026-11-07 |
| MOTS-c as a predictor of coronary lesions and complexity in patients with stable coronary artery disease. | mots-c | Study recordCross-sectional study | — | — | 2026-11-07 |
| Hair fall on hair pull test | ghk-cu | Risk of biasUncontrolled pilot study | Serious concern | 1000 | 2026-11-07 |
| Vellus hairs, terminal hairs and shaft diameter | ghk-cu | Risk of biasUncontrolled pilot study | Serious concern | 1000 | 2026-11-07 |
| Patient-perceived benefit | ghk-cu | Risk of biasUncontrolled pilot study | Serious concern | 1000 | 2026-11-07 |
| Total hair count | ghk-cu | Risk of biasUncontrolled pilot study | Serious concern | 1000 | 2026-11-07 |
| Tolerability | ghk-cu | Risk of biasUncontrolled pilot study | Serious concern | 1000 | 2026-11-07 |
| Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study. | ghk-cu | Study recordUncontrolled pilot study | — | 1000 | 2026-11-07 |
| MOTS-c is associated with oxidative stress and arterial stiffness in peritoneal dialysis patients: a pilot study. | mots-c | Study recordCross-sectional study | — | 32 | 2026-11-07 |
| Expression Patterns of MOTS-c in Adrenal Tumors: Results from a Preliminary Study. | mots-c | Study recordCross-sectional study | — | — | 2026-11-07 |
| Systemic MOTS-c levels are increased in adults with obesity in association with metabolic dysregulation and remain unchanged after weight loss. | mots-c | Study recordCross-sectional study | — | — | 2026-11-07 |
| Elevated Serum Nardilysin Is Inversely Associated with Cardiovascular Disease in Kidney Transplant Recipients. | mots-c | Study recordCross-sectional study | — | 150 | 2026-11-07 |
| The Mitochondrial-Derived Peptide MOTS-c May Refine Mortality and Cardiovascular Risk Prediction in Chronic Hemodialysis Patients: A Multicenter Cohort Study. | mots-c | Study recordProspective cohort | — | 94 | 2026-11-07 |
| Serum Mitochondrial Open Reading Frame of the 12S rRNA-c (MOTS-c) Dynamics as a Complementary Marker of Treatment Response in Newly Diagnosed Multiple Myeloma: A Prospective Analysis. | mots-c | Study recordProspective cohort | — | 29 | 2026-11-07 |
| Circulating Mitochondrial Open Reading Frame of the 12S Ribosomal RNA Type-c Is Higher in Acute Coronary Syndrome and Is a Prognostic Biomarker for Major Cardiac Events in Patients With Acute Myocardial Infarction: A Case-Control Study. | mots-c | Study recordCase-control study | — | 400 | 2026-11-07 |
| AGEs-RAGE Axis and Mitochondrial-Derived Peptides in Advanced Chronic Kidney Disease: Interconnected Pathways Beyond Inflammation and Nutrition. | mots-c | Study recordCross-sectional study | — | — | 2026-11-07 |
| Insights into the Biomarker Potential of Humanin and Mots-c Expression and Telomere Length in Alzheimer's Disease. | mots-c | Study recordCase-control study | — | — | 2026-11-07 |
| Reduced serum levels of mitochondria-derived peptide MOTS-c in patients with obstructive sleep apnea. | mots-c | Study recordCross-sectional study | — | 77 | 2026-11-07 |
| Circulating levels of MOTS-c in patients with breast cancer treated with metformin. | mots-c | Study recordRandomized controlled trial | — | — | 2026-11-07 |
| Diagnostic relevance of Humanin, GAS5 and miR-21/miR-103 in prostate disease risk stratification. | mots-c | Study recordCross-sectional study | — | 375 | 2026-11-07 |
| Circulating mitochondrial biomarkers in acute coronary syndrome. | mots-c | Study recordCase-control study | — | 38 | 2026-11-07 |
| MOTS-c Levels and Sarcopenia Risk in Chronic Peritoneal Dialysis Patients: A Pilot Study. | mots-c | Study recordCross-sectional study | — | 32 | 2026-11-07 |
| Could MOTS-c Levels in Children with Type 1 Diabetes Mellitus Be an Indicator for Early Diabetic Kidney Disease? | mots-c | Study recordCross-sectional study | — | — | 2026-11-07 |
| MOTS-c as a Potential Diagnostic-prognostic Biomarker for Myocardial Infarction. | mots-c | Study recordCase-control study | — | — | 2026-11-07 |
| Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization. | mots-c | Study recordRandomized controlled trial | — | 19 | 2026-11-07 |
| Evaluation of vascular peroxidase 1, humanin, MOTS-c and miR-200c expression levels in untreated preeclampsia patients. | mots-c | Study recordCross-sectional study | — | — | 2026-11-07 |
| Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors. | mots-c | Study recordRandomized controlled trial | — | 49 | 2026-11-07 |
| Wrinkles | ghk-cu | Risk of biasOther design | Serious concern | — | 2026-11-07 |
| Pain during treatment | ghk-cu | Risk of biasCase report | Serious concern | 1 | 2026-11-07 |
| Adverse effects | ghk-cu | Risk of biasCase report | Serious concern | 1 | 2026-11-07 |
| Scar appearance (Manchester Scoring Scale) | ghk-cu | Risk of biasSingle-arm trial | Serious concern | — | 2026-11-07 |
| Skin texture (smoothness, roughness, scaliness; Visioscan) | ghk-cu | Risk of biasSingle-arm trial | Serious concern | — | 2026-11-07 |
| Adverse effects and in-use tolerability | ghk-cu | Risk of biasSingle-arm trial | Serious concern | — | 2026-11-07 |
| Adherent Scalp Flaking Score (ASFS) | ghk-cu | Risk of biasSingle-arm trial | Serious concern | — | 2026-11-07 |
| Clinical pigmentation and erythema | ghk-cu | Risk of biasUncontrolled pilot study | Serious concern | — | 2026-11-07 |
| Melanin index | ghk-cu | Risk of biasUncontrolled pilot study | Serious concern | — | 2026-11-07 |
| Erythema index | ghk-cu | Risk of biasUncontrolled pilot study | Serious concern | — | 2026-11-07 |
| Dermal type IV collagen and procollagen | ghk-cu | Risk of biasUncontrolled pilot study | Serious concern | — | 2026-11-07 |
| Skin barrier condition | ghk-cu | Risk of biasOther design | Serious concern | — | 2026-11-07 |
| p63-positive cells along basement membrane | ghk-cu | Risk of biasUncontrolled pilot study | Serious concern | — | 2026-11-07 |
| Percentage area closure of plantar ulcers | ghk-cu | Risk of biasRandomized controlled trial | Some concerns | — | 2026-11-07 |
| Proportion of patients healing 98% or better | ghk-cu | Risk of biasRandomized controlled trial | Some concerns | — | 2026-11-07 |
| Rate of ulcer closure | ghk-cu | Risk of biasRandomized controlled trial | Some concerns | — | 2026-11-07 |
| Percentage area closure in larger plantar ulcers (>100 mm2 at entry) | ghk-cu | Risk of biasRandomized controlled trial | High certainty | — | 2026-11-07 |
| Incidence of ulcer infection | ghk-cu | Risk of biasRandomized controlled trial | High certainty | — | 2026-11-07 |
| Blood biomarkers of heart, liver, kidney, thyroid function and blood glucose | bpc-157 | Risk of biasUncontrolled pilot study | Serious concern | 2 | 2026-11-07 |
| Side effects / tolerability | bpc-157 | Risk of biasUncontrolled pilot study | Serious concern | 2 | 2026-11-07 |
| Improvement in knee pain (patient-reported) | bpc-157 | Risk of biasCase series | Serious concern | 17 | 2026-11-07 |
| Global Response Assessment | bpc-157 | Risk of biasUncontrolled pilot study | Serious concern | 12 | 2026-11-07 |
| Resolution of post-treatment erythema | ghk-cu | Risk of biasRandomized controlled trial | High certainty | — | 2026-11-07 |
| Patient-rated symptom resolution | bpc-157 | Risk of biasUncontrolled pilot study | Serious concern | 12 | 2026-11-07 |
| Adverse events and dropouts | bpc-157 | Risk of biasUncontrolled pilot study | Serious concern | 12 | 2026-11-07 |
| Overall improvement in wrinkles | ghk-cu | Risk of biasRandomized controlled trial | High certainty | — | 2026-11-07 |
| Overall improvement in skin appearance | ghk-cu | Risk of biasRandomized controlled trial | High certainty | — | 2026-11-07 |
| Patient-reported improvement in overall skin quality (questionnaire) | ghk-cu | Risk of biasRandomized controlled trial | High certainty | — | 2026-11-07 |
| Periorbital wrinkles (crow's feet) | ghk-cu | Risk of biasCase report | Serious concern | 1 | 2026-11-07 |
| Dermal collagen on histology | ghk-cu | Risk of biasCase report | Serious concern | 1 | 2026-11-07 |
| Dermal matrix proteins (collagen IV, fibrillin-1, procollagen type 1, tropoelastin) | ghk-cu | Risk of biasCase report | Serious concern | 1 | 2026-11-07 |
| Phase II trial of PL 14736 (BPC-157) enema in mild-to-moderate ulcerative colitis | bpc-157 | Study recordRandomized controlled trial | — | — | 2026-11-07 |
| Phase 1 safety, tolerability and pharmacokinetics of PL 14736 (BPC-157) in healthy male volunteers | bpc-157 | Study recordOther design | — | — | 2026-11-07 |
| Augmented Skin Beneficial Effects of Thermus Thermophilus and Bacillus Subtilis Mixed-Culture Ferment Extract by Tripeptide GHK-Cu. | ghk-cu | Study recordOther design | — | — | 2026-11-07 |
| Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. | ghk-cu | Study recordRandomized controlled trial | — | — | 2026-11-07 |
| Significant improvement in crow's feet after treatment with Jet-M and a mixed solution of copper-GHK, oligo-hyaluronic acid, rhodiolar extract, tranexamic acid, and β-glucan (GHR formulation). | ghk-cu | Study recordCase report | — | 1 | 2026-11-07 |
| Efficacy and Safety Assessment of ThriveCo Scar Fader Gel With Scarcede™ in the Treatment of Skin Scars. | ghk-cu | Study recordSingle-arm trial | — | — | 2026-11-07 |
| An Assessment of the Safety, Efficacy, and Tolerability of a Novel Scalp Treatment Regimen Combining a Hydroxy Acid-Based Scrub and Copper Tripeptide Serum in the Management of Seborrheic Dermatitis in Adults. | ghk-cu | Study recordSingle-arm trial | — | — | 2026-11-07 |
| The effects of hydroporation on melasma with anti-aging cocktail. | ghk-cu | Study recordUncontrolled pilot study | — | — | 2026-11-07 |
| Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. | ghk-cu | Study recordRandomized controlled trial | — | — | 2026-11-07 |
| Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. | bpc-157 | Study recordUncontrolled pilot study | — | 2 | 2026-11-07 |
| Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. | bpc-157 | Study recordCase series | — | 17 | 2026-11-07 |
| Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. | bpc-157 | Study recordUncontrolled pilot study | — | 12 | 2026-11-07 |
| The Mitochondrial Antioxidant SS-31 Modulates Oxidative Stress, Endoplasmic Reticulum Stress, and Autophagy in Type 2 Diabetes. | elamipretide | Study recordOther design | — | — | 2026-11-07 |
| Are serum MOTS-c levels and MOTS-c m.1382A>C polymorphism related to polycystic ovary syndrome? | mots-c | Study recordCase-control study | — | — | 2026-11-07 |
| Reduced serum and skeletal muscle MOTS c levels in women with polycystic ovary syndrome are associated with mitochondrial dysfunction. | mots-c | Study recordCase-control study | — | 80 | 2026-11-07 |
| MOTS-C levels ın ındividuals with and without obesity and ıts association with ınflammation, insulin resistance and endothelial dysfunction. | mots-c | Study recordCross-sectional study | — | 85 | 2026-11-07 |
| Reduced Circulating MOTS-c Levels in Hashimoto's Thyroiditis Reflect Integrated Autoimmune and Metabolic Dysregulation: A Cross-Sectional Study. | mots-c | Study recordCross-sectional study | — | 180 | 2026-11-07 |
| The Association Between Serum MOTS-c Levels and Myocardial Ischemia-Reperfusion Injury in Patients with Acute Myocardial Infarction: A Cross-Sectional Study. | mots-c | Study recordCross-sectional study | — | 72 | 2026-11-07 |